GSK Set for $500 Million Payment From mRNA Lawsuit Settlement

CureVac NV has settled a long-running patent dispute over mRNA vaccines with Pfizer Inc. and BioNTech SE in the US, which will see CureVac’s former collaborator GSK Plc receive as much as $500 million and 1% of royalties from future vaccine sales.

Source: Bloomberg Markets.